



AP35478 066123.0125
PATENT

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of claims

1-21. (Canceled)

22. (New) A method for identifying drugs against mycobacterial species having a two-component system of DevR-DevS, said method comprising:

- a) providing a system in which recombinant DevR and DevS are expressed;
- b) in the presence of a test compound, autophosphorylating DevS protein and thereafter transferring phosphoryl moiety to DevR;
- c) analyzing the reaction products by SDS-PAGE or high throughput format; and
- d) determining the anti-mycobacterial drug potential of the test compound; wherein the drug potential of the test compound is inversely proportional to (i) the degree of autophosphorylation of DevS protein, (ii) the degree of phosphotransfer from phosphorylated DevS to DevR, and (iii) the degree of loss of phosphate-associated radioactivity from DevS or DevR in a reaction containing DevS and DevR.

03/06/2006 HHARZI1 00000066 024377 10687402

04 FC:1201 225.00 DA 775.00 OP

23. (New) A method for identifying drugs against mycobacterial species having a two-component system of DevR-DevS, said method comprising:

- a) providing a system in which recombinant DevR and a recombinant single domain derivative of DevS are expressed;
- b) in the presence of a test compound, autophosphorylating a single domain derivative of DevS protein and thereafter transferring phosphoryl moiety to DevR;
- c) analyzing the reaction products by SDS-PAGE or high throughput format; and
- d) determining the anti-mycobacterial drug potential of the test compound; wherein the drug potential of the test compound is inversely proportional to (i) the degree of autophosphorylation of a single domain derivative of DevS protein, (ii) the degree of phosphotransfer from a phosphorylated single domain derivative of DevS to DevR, and (iii) the degree of loss of phosphate-associated radioactivity from a single domain derivative of DevS or DevR in a reaction containing a single domain derivative of DevS and DevR.

24. (New) The method as claimed in claim 23, wherein the DevS derivative is selected from the group consisting of DevS₂₀₁, DevS₅₇₈, DevS₂₀₁-H395Q, DevS₂₀₁-H397Q, DevS₂₀₁-H397A, and DevS₂₀₁-N503D.

25. (New) A method for identifying drugs against mycobacterial species having a two-component system of DevR-DevS, said method comprising:

- a) providing a system in which a recombinant single domain derivative of DevR and recombinant DevS are expressed;
- b) in the presence of a test compound, autophosphorylating DevS protein and thereafter transferring phosphoryl moiety to a single domain derivative of DevR;
- c) analyzing the reaction products by SDS-PAGE or high throughput format; and
- d) determining the anti-mycobacterial drug potential of the test compound; wherein the drug potential of the test compound is inversely proportional to (i) the degree of autophosphorylation of DevS protein, (ii) the degree of phosphotransfer from phosphorylated DevS to a single domain derivative of DevR, and (iii) the degree of loss of phosphate-associated radioactivity from DevS or a single domain derivative of DevR in a reaction containing DevS and a single domain derivative of DevR.

26. (New) The method as claimed in claim 25, wherein the DevR derivative is DevRN₁₄₅ or the mutant protein is selected from the group consisting of DevR-D8N, DevR-D9N, DevR-D54V, DevR-D54N and DevR-K104E.

27. (New) A method for identifying drugs against mycobacterial species having a two-component system of DevR-DevS, said method comprising:

- a) providing a system in which a recombinant single domain derivative of DevR and a recombinant single domain derivative of DevS are expressed;
- b) in the presence of a test compound, autophosphorylating a single domain derivative of DevS protein and thereafter transferring phosphoryl moiety to a single domain derivative of DevR;
- c) analyzing the reaction products by SDS-PAGE or high throughput format; and
- d) determining the anti-mycobacterial drug potential of the test compound; wherein the drug potential of the test compound is inversely proportional to (i) the degree of autophosphorylation of a single domain derivative of DevS protein, (ii) the degree of phosphotransfer from a phosphorylated single domain derivative of DevS to a single domain derivative of DevR, and (iii) the degree of loss of phosphate-associated radioactivity from a single domain derivative of DevS or a single domain derivative of DevR in a reaction containing a single domain derivative of DevS and a single domain derivative of DevR.

28. (New) The method as claimed in claim 27, wherein the DevS derivative is selected from the group consisting of DevS₂₀₁, DevS₅₇₈, DevS₂₀₁-H395Q, DevS₂₀₁-H397Q, DevS₂₀₁-H397A, and DevS₂₀₁-N503D.

29. (New) The method as claimed in claim 27, wherein the DevR derivative is DevRN₁₄₅ or the mutant protein is selected from the group consisting of DevR-D8N, DevR-D9N, DevR-D54V, DevR-D54N and DevR-K104E.

30. (New) A method for identifying drugs against mycobacterial species having a two-component system of DevR-Rv2027c, said method comprising:

- a) providing a system in which recombinant DevR and Rv2027c are expressed;
- b) in the presence of a test compound, autophosphorylating Rv2027c protein and thereafter transferring phosphoryl moiety to DevR;
- c) analyzing the reaction products by SDS-PAGE or high throughput format; and
- d) determining the anti-mycobacterial drug potential of the test compound; wherein the drug potential of the test compound is inversely proportional to (i) the degree of autophosphorylation of Rv2027c protein, (ii) the degree of phosphotransfer from phosphorylated Rv2027c to DevR, and (iii) the degree of loss of phosphate-associated radioactivity from Rv2027c or DevR in a reaction containing Rv2027c and DevR.

31. (New) A method for identifying drugs against mycobacterial species having a two-component system of DevR-Rv2027c, said method comprising:

- a) providing a system in which recombinant DevR and a recombinant single domain derivative of Rv2027c are expressed;
- b) in the presence of a test compound, autophosphorylating a single domain derivative of Rv2027c protein and thereafter transferring phosphoryl moiety to DevR;
- c) analyzing the reaction products by SDS-PAGE or high throughput format; and
- d) determining the anti-mycobacterial drug potential of the test compound; wherein the drug potential of the test compound is inversely proportional to (i) the degree of autophosphorylation of a single domain derivative of Rv2027c protein, (ii) the degree of phosphotransfer from a phosphorylated single domain derivative of Rv2027c to DevR, and (iii) the degree of loss of phosphate-associated radioactivity from a single domain derivative of Rv2027c or DevR in a reaction containing a single domain derivative of Rv2027c and DevR.

32. (New) The method as claimed in claim 31, wherein the Rv2027c derivative is selected from the group consisting of Rv2027₁₉₄ and Rv2027₁₉₄-H392Q.

33. (New) A method for identifying drugs against mycobacterial species having a two-component system of DevR-Rv2027c, said method comprising:

- a) providing a system in which a recombinant single domain derivative of DevR and recombinant Rv2027c are expressed;
- b) in the presence of a test compound, autophosphorylating Rv2027c protein and thereafter transferring phosphoryl moiety to a single domain derivative of DevR;
- c) analyzing the reaction products by SDS-PAGE or high throughput format; and
- d) determining the anti-mycobacterial drug potential of the test compound; wherein the drug potential of the test compound is inversely proportional to (i) the degree of autophosphorylation of Rv2027c protein, (ii) the degree of phosphotransfer from phosphorylated Rv2027c to a single domain derivative of DevR, and (iii) the degree of loss of phosphate-associated radioactivity from Rv2027c or a single domain derivative of DevR in a reaction containing Rv2027c and a single domain derivative of DevR.

34. (New) The method as claimed in claim 33, wherein the DevR derivative is DevRN₁₄₅ or the mutant protein is selected from the group consisting of DevR-D8N, DevR-D9N, DevR-D54V, DevR-D54N and DevR-K104E.

35. (New) A method for identifying drugs against mycobacterial species having a two-component system of DevR-Rv2027c, said method comprising:

- a) providing a system in which a recombinant single domain derivative of DevR and a recombinant single domain derivative of Rv2027c are expressed;
- b) in the presence of a test compound, autophosphorylating a single domain derivative of Rv2027c protein and thereafter transferring phosphoryl moiety to a single domain derivative of DevR;
- c) analyzing the reaction products by SDS-PAGE or high throughput format; and
- d) determining the anti-mycobacterial drug potential of the test compound; wherein the drug potential of the test compound is inversely proportional to (i) the degree of autophosphorylation of a single domain derivative of Rv2027c protein, (ii) the degree of phosphotransfer from a phosphorylated single domain derivative of Rv2027c to a single domain derivative of DevR, and (iii) the degree of loss of phosphate-associated radioactivity from a single domain derivative of Rv2027c or a single domain derivative of

DevR in a reaction containing a single domain derivative of Rv2027c and a single domain derivative of DevR.

36. (New) The method as claimed in 35, wherein the Rv2027c derivative is selected from the group consisting of Rv2027₁₉₄ and Rv2027₁₉₄-H392Q.

37. (New) The method as claimed in claim 35, wherein the DevR derivative is DevRN₁₄₅ or the mutant protein is selected from the group consisting of DevR-D8N, DevR-D9N, DevR-D54V, DevR-D54N and DevR-K104E.